Literature DB >> 21098759

Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

Kelly Metcalfe1, Jan Lubinski, Henry T Lynch, Parviz Ghadirian, William D Foulkes, Charmaine Kim-Sing, Susan Neuhausen, Nadine Tung, Barry Rosen, Jacek Gronwald, Peter Ainsworth, Kevin Sweet, Andrea Eisen, Ping Sun, Steven A Narod.   

Abstract

Women who carry a deleterious mutation in BRCA1 or BRCA2 have high lifetime risks of breast and ovarian cancers. However, the influence of a family history of these cancers on these risks in women with BRCA mutations is unclear. We calculated cancer incidence rates for a multinational cohort comprising 3011 women with BRCA1 or BRCA2 mutations who were followed up for a mean of 3.9 years, during which time 243 incident breast or ovarian cancers were recorded. The 10-year cumulative risks of breast cancer were 18.1% (95% confidence interval [CI] = 13.3% to 22.8%) for women with a BRCA1 mutation and 15.2% (95% CI = 9.1% to 21.2%) for women with a BRCA2 mutation. Among women with a BRCA1 mutation, the risk of breast cancer increased by 1.2-fold for each first-degree relative with breast cancer before age 50 years (hazard ratio [HR] = 1.21; 95% confidence interval [CI] = 0.94 to 1.57) and the risk of ovarian cancer increased by 1.6 fold for each first- or second-degree relative with ovarian cancer (HR = 1.61; 95% CI = 1.21 to 2.14). Among women with a BRCA2 mutation, the risk of breast cancer increased by 1.7-fold for each first-degree relative younger than 50 years with breast cancer (HR = 1.67; 95% CI = 1.04 to 2.07).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098759     DOI: 10.1093/jnci/djq443

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  35 in total

Review 1.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?

Authors:  K A Metcalfe; A Eisen; J Lerner-Ellis; S A Narod
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

3.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

Review 4.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 5.  Germline Mutations in Triple-Negative Breast Cancer.

Authors:  Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2017-02-24       Impact factor: 2.860

6.  A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

Authors:  S A Narod; N Tung; J Lubinski; T Huzarski; M Robson; H T Lynch; S L Neuhausen; P Ghadirian; C Kim-Sing; P Sun; W D Foulkes
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

7.  Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.

Authors:  Samuele Lodovichi; Martina Vitello; Tiziana Cervelli; Alvaro Galli
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

8.  The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?

Authors:  Natalia Teixeira; Annemieke van der Hout; Jan C Oosterwijk; Janet R Vos; Peter Devilee; Klaartje van Engelen; Hanne Meijers-Heijboer; Rob B van der Luijt; Mieke Kriege; Arjen R Mensenkamp; Matti A Rookus; Kees E van Roozendaal; Marian J E Mourits; Geertruida H de Bock
Journal:  Eur J Hum Genet       Date:  2018-02-26       Impact factor: 4.246

9.  Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.

Authors:  Dorothea Gadzicki; D Gareth Evans; Hilary Harris; Claire Julian-Reynier; Irmgard Nippert; Jörg Schmidtke; Aad Tibben; Christi J van Asperen; Brigitte Schlegelberger
Journal:  J Community Genet       Date:  2011-03-02

Review 10.  Breast cancer risks and risk prediction models.

Authors:  Christoph Engel; Christine Fischer
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.